Cantor Fitzgerald maintains Overweight rating on Omeros with $22 price target ahead of CHMP review
Cantor Fitzgerald kept an Overweight rating on Omeros Corp. and set a $22.00 price target, citing the company's strong Q2 results and its pipeline. The firm highlighted the upcoming presentation of the Yartemlea monoclonal antibody to the EU Committee for Medicinal Products for Human Use (CHMP) on Oct. 14, 2026. Omeros reported Q2 revenue of $28.5 million and adjusted earnings of $0.02 per share, well above analysts' expectations.
Why it matters
The analyst’s target implies roughly 16.5% upside from the $18.88 close, which may attract investors if the CHMP opinion is favorable. Cantor Fitzgerald noted that a positive CHMP outcome could lead to a revision of its estimates.
Key facts
- 1Cantor Fitzgerald reiterated an Overweight rating on Omeros Corp. and set a $22.00 price target. investing.com
- 2The stock was trading at $18.88 at the time of the note. investing.com
- 3Omeros reported Q2 revenue of $28.5 million. investing.com
- 4Adjusted earnings were $0.02 per share for Q2. investing.com
- 5Omeros presented its Yartemlea case to the CHMP on Oct. 14, 2026 at 10 a.m. ET, with a final opinion expected by the end of the week. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.